Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide

NCT03065790 · clinicaltrials.gov ↗

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Adequate recruitment was not reached to continue the study.

Conditions

Non-Hodgkin Lymphoma

Interventions

DIAGNOSTIC_TEST: 2-Deoxy-2-[18F]fluoro-D-glucose (FDG)

Sponsor

Abramson Cancer Center at Penn Medicine